Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography (Q74734309)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12213575%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

title

Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12213575%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

author name string

Marie Knockaert

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12213575%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Laurent Meijer

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12213575%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

language of work or name

English

0 references

publication date

1 September 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12213575%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

published in

Biochemical Pharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12213575%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12213575%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

issue

5-6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12213575%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

page(s)

819-825

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12213575%20AND%20SRC:MED&resulttype=core&format=json

describes a project that uses

12 November 2019

affinity chromatography

1 reference

based on heuristic

inferred from title

cites work

Cyclin-dependent kinases: engines, clocks, and microprocessors

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

CDK inhibition and cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Cyclin-dependent kinase inhibitors: novel anticancer agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Small molecule modulators of cyclin-dependent kinases for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

A link between cell cycle and cell death: Bax and Bcl-2 modulate Cdk2 activation during thymocyte apoptosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Preclinical and clinical development of cyclin-dependent kinase modulators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: biochemical identification using Xenopus egg extracts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Intracellular Targets of Paullones. Identification following affinity purification on immobilized inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Mechanisms of action of flavopiridol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

Potent interaction of flavopiridol with MRP1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901144-9

10.1016/S0006-2952(02)01144-9

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12213575%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference